Clinical Trials Browser

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05414500 2026-04-09

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

10 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT06698003 2026-03-05

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Phase 2 Recruiting

134 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06235281 2026-02-27

PLIGHT

Phase EARLY_PHASE1 Suspended

20 enrolled

Lymphoid

Mycosis Fungoides

NCT04848064 2026-02-10

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Phase 1 Recruiting

12 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05956041 2026-01-07

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Phase 2 Recruiting

23 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Phase 2 Recruiting

34 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04256018 2025-07-02

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Phase 1/2 Terminated

5 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02281409 2021-04-23

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Phase 1/2 Completed

17 enrolled 13 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02946671 2020-03-06

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Phase 1 Completed

16 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mouth Neoplasms, Stomach Neoplasms

NCT01929486 2016-02-17

Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.

Phase 1 Unknown

58 enrolled

Other solid neoplasm

Solid Tumor

Clinical Trials

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

PLIGHT

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.